Tel: 01789 267520

AveXis Issues Community Statement on the SPR1NT Trial

08 May 2018

AveXis, the gene therapy company developing a new approach to treat SMA known as AVXS‐101, recently treated the first patient in a new study known as SPR1NT. They have provided the following community statement:

Community statement